Skip to main content

Table 1 Patient Demographics and Outcomes

From: Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

Patient Identifier Gender Age Disease Site Previous Therapy Baseline Tumor Mutationa Trial Armb Best Clinical outcomec Overall Survivald Progression Free Survivald
1 F 82 Skin Temodar 3 cycles (1.5 yrs. prior) BRAF V 600 K OBS PD 6.3 3.2
2 M 74 Skin and chest wall IL-2, IFNα, ipilimumab BRAF V600E and NRAS NR PD 14.0 2.0
3 F 82 Skin NRAS Q61R NR PD 13.6 2.1
4 M 74 Skin None NR PD 1.0 0.8
5 M 44 Skin and brain BRAF V600E NR PD 0.6 0.4
6 M 67 Nasal cavity IFNα, vaccine + ipilimumab, IL-2 None IFN SD 39.8 5.5
7 M 42 Skin and lymph nodes Ipilimumab, dacarbazine, IFNα, carboplatin + paclitaxel (2 mo. prior), pembrolizumab None OBS SD 20.0 7.2
8 F 74 Skin IFNα, DC vaccine, ipilimumab, pembrolizumab (11–090) None IFN SD 13.0 8.7
9 M 66 Skin and lymph nodes IFN, ipi, anti-PD-1 NRAS Q61K IFN SD 27.4 5.7
10 M 61 Skin and retroperitoneum Ipilimumab NRAS OBS PR 44.3 13.4
11 M 56 Skin and lymph nodes IFNα, ipilimumab, IL-2, dacarbazine None NR PD 14.8 1.7
12 M 44 Lymph nodes NRAS OBS SD 41.7 3.9
13 M 74 Skin IFNα None OBS NED 42.5 18.4
14 F 58 Skin IFNα BRAF V600E NR PD 28.4 1.7
15 F 52 Skin Ipilimumab NRAS IFN NED 42.7 6.9
16 F 75 Vulva IFNα None IFN NED 38.6 9.3
17 M 64 Lymph nodes IFNα, ipi, IL-2 + anti-VEGF BRAF V600E NR PD 4.6 2.3
18 M 68 Skin IFNα None OBS NED 39.9 5.0
19 M 64 Skin IFNα, DC vaccine None OBS SD 3.5 3.2
20 M 60 Skin None IFN PR 40.1 7.3
21 F 61 Skin IFNα None OBS NED 20.2 19.2
22 F 70 Lymph nodes Ipi + IFNα None OBS PD 3.0 2.0
23 M 28 Lung IL-2 + anti-VEGF None NR PD 11.2 2.1
24 F 42 Muscle Ipi + Nivo, IL-2 None OBS PD 3.2 2.1
25 M 52 Skin and lymph nodes BRAF V600K NR PD 0.6 0.6
26 M 60 Skin IFNα BRAF V600E OBS NED 36.1 3.6
27 F 59 Skin n.t. OBS NED 35.8 13.7
28 M 47 Lymph nodes IFNα, Nivo, Ipi BRAF V600E NR PD 11.8 1.6
29 M 60 Skin n.t. IFN NED 32.3 14.0
30 F 45 Skin None IFN NED 37.5 37.5
31 M 66 Skin IFNα None OBS NED 37.3 30.7
32 F 41 Skin IFNα n.t. OBS NED 26.5 2.5
33 F 46 Lower limb and breast IFNα, Ipi, IL-2, Pembro BRAF V600E NR PD 1.6 0.9
34 M 88 Nasal cavity and lung IFNα, Ipi, Pembro None OBS SD 8.2 3.3
35 F 52 Skin and lymph node GM-CSF (14 yrs. prior), IL-2, ipi BRAF V600E IFN SD 24.2 13.0
  1. aTumor mutations identified in available baseline samples tested by clinical pathology sequencing test and/or by NanoString SNV panel, “n.t.” not tested, “None” tested and no mutation detected in panel
  2. bTrial arm: NR not randomized due to early progression, IFN randomized to IFN, OBS randomized to observation
  3. cPD progressive disease, SD stable disease, PR partial response, NED no evidence of disease (all by RECIST)
  4. dTime in months